These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 30242549)

  • 1. Thyroid disorders induced by checkpoint inhibitors.
    Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
    Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine sequelae of immune checkpoint inhibitors.
    Ntali G; Kassi E; Alevizaki M
    Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
    Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
    Di Dalmazi G; Ippolito S; Lupi I; Caturegli P
    Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
    Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
    Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
    Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
    Deligiorgi MV; Liapi C; Trafalis DT
    Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
    Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
    Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
    Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
    Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
    González-Rodríguez E; Rodríguez-Abreu D;
    Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune checkpoint inhibitors and endocrinological side effects].
    Jørgensen LB; Bastholt L; Yderstræde K
    Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
    Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
    Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
    Deligiorgi MV; Panayiotidis MI; Trafalis DT
    Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.